Survey assessing prospective patient’s short-term treatment satisfaction and Quality of Life in patients with Hidradenitis Suppurativa initiated on Cosentyx (Secukinumab) in routine clinical practice in Saudi Arabia

drug protocol number
CAIN457MSA
drug sponsor
Novartis
drug study
Secukinumab
drug trial site
King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah)
drug status
Ongoing
drug phase